MedTrace Logo

Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT

NCT06039436 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2023-10-24

No results posted yet for this study

Summary

To evaluate the safety and efficacy of Single Umbilical Cord blood transplantation (sUCBT) containing low dose ATG based conditioning regimen in the treatment of acquired Severe Aplastic Anemia (SAA).

Conditions

  • Severe Aplastic Anemia

Interventions

DRUG

Anti-Thymocyte Globulin (Rabbit)

Indications for trial stopping: subjects occur pregnancy events, severe organ function impairments, or emergency events related or unrelated to treatment; or subjects are unwilling to continue participating in the clinical trial.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Xiaoyu Zhu, ph.D · The First Affiliated Hospital of University of Science and Technology of China (Anhui Provicial Hospital)

Eligibility

Min Age
1 Year
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2025-04-30
Completion
2025-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06039436 on ClinicalTrials.gov